The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
The freshly infused capital will primarily be deployed towards expansion and research & development
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
The products will be manufactured in Goa India and marketed & distributed in Australian markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), will be distributed in the US by Glenmark Therapeutics, USA.
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Subscribe To Our Newsletter & Stay Updated
